Boenning & Scattergood Initiates Coverage on Exelixis (EXEL) with a Neutral
More News related to EXEL
- Exelixis Announces December 1 Webcast of Presentation at Piper Jaffray's 21st Annual Healthcare Conference
- Exelixis Announces Webcast of Its Fifth Annual R&D Day on December 2
- Unusual 11 Mid-Day Movers 11/18: ABK, LZB, NLST, LDK Higher; ONCY, NANO, EXEL, VRUS Lower
- Exelixis Reports Encouraging Phase 1 Data for the PI3K Inhibitor Xl147 (SAR245408) in Combination with Erlotinib at the AACR-NCI-EORTC Conference
- Morning Movers 11/18: ABK, CHS, LDK, RDN Higher; ONCY, NANO, EXEL, ADSK, CNQR Lower
More News related to New Coverage
- Bank of America Initiates Coverage on Tenneco (TEN) with a Buy
- Needham & Co Initiates Coverage on Cantel Medical (CMN) with a Buy
- William Blair Initiates Coverage on Air Products and Chemicals (APD) with an Outperform
- Jefferies & Co Initiates Coverage on Under Armour (UA) with a Buy
- Calyon Securities Initiates Coverage on Teck Resources (TCK) with an Outperform
Boenning & Scattergood initiates coverage on Exelixis (Nasdaq: EXEL) with a Neutral.
To see more analyst ratings on EXEL Click Here.
Exelixis, Inc. (Exelixis) is developing therapies for cancer and other serious diseases. Through its drug discovery and development activities, the Company is building a portfolio of novel compounds.
Related Categories
New CoverageStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
